List of Excipients in Branded Drug PROVERA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	PROVERA	medroxyprogesterone acetate	0009-0064	CALCIUM STEARATE
Pharmacia & Upjohn Company LLC	PROVERA	medroxyprogesterone acetate	0009-0064	FD&C YELLOW NO. 6
Pharmacia & Upjohn Company LLC	PROVERA	medroxyprogesterone acetate	0009-0064	LACTOSE
Pharmacia & Upjohn Company LLC	PROVERA	medroxyprogesterone acetate	0009-0064	MINERAL OIL
Pharmacia & Upjohn Company LLC	PROVERA	medroxyprogesterone acetate	0009-0064	SORBIC ACID
Pharmacia & Upjohn Company LLC	PROVERA	medroxyprogesterone acetate	0009-0064	STARCH, CORN

Provera Excipient Strategy and Commercial Opportunities for Medroxyprogesterone Acetate Tablets

Last updated: October 17, 2026

Provera is the oral tablet brand for medroxyprogesterone acetate, a synthetic progestin used for secondary amenorrhea, abnormal uterine bleeding caused by hormonal imbalance, and endometrial protection in selected estrogen-containing hormone therapy regimens. Its commercial opportunity is primarily generic manufacturing, differentiated excipient design, contract development and manufacturing, and lifecycle products rather than protection of the original branded tablet.

The highest-value formulation strategies are lactose-free tablets, improved low-dose content uniformity, reduced tablet burden, supply-stable excipient systems, and patient-friendly packaging. A new excipient platform will not create meaningful exclusivity by itself. Commercial value must come from regulatory approval, manufacturing reliability, tolerability, channel access, or a separately patentable delivery system.

What is Provera and which formulations are commercially relevant?

Provera contains medroxyprogesterone acetate, or MPA, in oral tablet strengths of 2.5 mg, 5 mg, and 10 mg. The reference product is approved under FDA NDA 011839 for several gynecologic indications. The product is not the same as depot medroxyprogesterone acetate injectable suspension, marketed as Depo-Provera, which has a different route, formulation, excipient profile, regulatory pathway, and commercial market.[1]

Attribute	Provera oral tablets
Active ingredient	Medroxyprogesterone acetate
Dosage form	Immediate-release oral tablet
Listed strengths	2.5 mg, 5 mg, 10 mg
Primary indications	Secondary amenorrhea; abnormal uterine bleeding; endometrial protection with estrogen therapy
Reference sponsor	Pfizer
FDA approval pathway	NDA reference product; generic products through ANDA
Typical formulation type	Immediate-release compressed tablet
Principal commercial competitors	Generic medroxyprogesterone acetate tablet manufacturers
Main development constraint	Demonstrating pharmaceutical equivalence, bioequivalence, content uniformity, dissolution, stability, and commercial manufacturability

The oral product is a low-dose hormonal tablet. MPA has high potency relative to tablet mass, making blend uniformity and segregation control more important than the nominal tablet weight suggests.

What excipients are used in Provera tablets?

The Provera labeling identifies conventional tablet excipients, including lactose monohydrate, sucrose, corn starch, calcium stearate, and talc. Colorants can vary by strength and presentation. Exact inactive ingredients should be assessed from the applicable FDA label and current manufacturer-specific labeling because generic products may use different excipient systems.[1]

The reference formulation is commercially important as a benchmark, but an ANDA applicant generally does not need to copy every excipient. A generic may use a different qualitative or quantitative excipient composition if it meets applicable pharmaceutical equivalence, bioequivalence, quality, labeling, and safety requirements.[2]

Functional role of the principal excipients

Excipient class	Likely function in an MPA tablet	Development considerations
Lactose monohydrate	Diluent and tablet bulk	Relevant to lactose intolerance, supplier qualification, moisture control, and powder flow
Sucrose	Diluent and mouthfeel modifier	Can affect hygroscopicity, sweetness, hardness, and stability
Corn starch	Diluent and disintegrant	Requires control of particle size, moisture, and gelatinization behavior
Calcium stearate	Lubricant	Excessive lubrication can slow dissolution and reduce tablet tensile strength
Talc	Glidant or anti-adherent	Requires control of source, particle size, microbial quality, and regulatory acceptability
Colorants	Product identification and strength differentiation	Can create allergen, market authorization, and supply-chain complications

A development program should not treat the reference excipients as a fixed formula. The commercial question is whether a replacement excipient system creates a measurable advantage without introducing dissolution, stability, bioequivalence, or manufacturing risk.

Which excipient strategies create the strongest commercial opportunities?

The strongest opportunities are formulation changes that address a defined patient, manufacturing, or market-access problem.

1. Lactose-free and low-sugar tablets

A lactose-free formulation can target patients who avoid lactose or who prefer a simpler excipient profile. Removing both lactose and sucrose may improve positioning for hospital formularies, specialty pharmacies, and certain international markets.

Potential replacement systems include:

• Microcrystalline cellulose
• Mannitol
• Dibasic calcium phosphate
• Pregelatinized starch
• Crospovidone or croscarmellose sodium
• Low-substituted hydroxypropyl cellulose

The main risks are altered dissolution, tablet size, hardness, friability, and powder flow. A lactose-free claim has commercial value only if it is accurate, consistently controlled, and clearly disclosed in labeling.

2. Improved low-dose content uniformity

The 2.5 mg and 5 mg strengths provide an opportunity for process differentiation. MPA is present at a low percentage of total tablet mass, so direct blending can create segregation and assay variability.

Higher-value process and formulation options include:

• Drug layering onto a carrier
• Wet granulation
• Dry granulation with engineered premixes
• Ordered mixing
• Controlled particle-size distribution
• Separate pre-blend of MPA with a high-surface-area excipient
• In-process blend uniformity monitoring
• Compression-force control linked to dissolution testing

A manufacturer that consistently produces narrow assay variability and robust scale-up may reduce batch failures and improve supply continuity. This is a stronger commercial proposition than simply replacing one filler with another.

3. Smaller tablets or modified tablet geometry

Patient adherence may improve with reduced tablet volume, especially where multiple medications are taken. A smaller tablet requires higher drug loading or more efficient excipients, but MPA’s potency makes this technically plausible.

Tablet geometry can also support:

• Better swallowing
• Differentiation among strengths
• Lower packaging volume
• Automated dispensing
• Child-resistant packaging compatibility
• Improved visual identification

The tradeoff is that a smaller tablet can increase compression sensitivity and create greater risk of capping, sticking, or weight variation.

4. Taste-masked or orally disintegrating products

An orally disintegrating tablet, mini-tablet, or fast-dissolving dosage form could address patients with swallowing difficulty. The commercial opportunity is more limited than for a conventional generic because the indication is primarily adult and the existing tablet is inexpensive.

A taste-masked product would require evaluation of:

• MPA bitterness
• Disintegration time
• Mouthfeel
• Residual grittiness
• Dose uniformity
• Moisture sensitivity
• Packaging barrier requirements
• Comparative exposure and food effects

A new dosage form may support a 505(b)(2) strategy rather than a conventional ANDA if it is not pharmaceutically equivalent to the reference tablet. That route may provide a differentiated label, but it also brings additional clinical, regulatory, and commercial expense.[3]

5. Supply-chain resilient excipient systems

A formulation using multiple qualified suppliers for critical excipients can reduce manufacturing interruptions. The most commercially exposed components are often those with limited global supply, narrow particle specifications, or high geographic concentration.

A resilient excipient strategy should include:

• Dual-source qualification for diluents and lubricants
• Alternate grades with comparable functionality
• Defined particle-size and moisture specifications
• Excipient change-control protocols
• Stability bridging plans
• Regional supplier qualification
• Contingency inventory for colorants and specialty disintegrants

This strategy may not support a patent claim, but it can improve contract manufacturing economics and product availability.

What formulation patents could protect a Provera follow-on product?

A generic Provera tablet is unlikely to obtain meaningful protection merely by using a standard excipient such as lactose, mannitol, microcrystalline cellulose, or crospovidone. These materials are widely known and commonly used.

Potentially protectable subject matter could include:

1. A narrowly defined MPA particle-size distribution that improves uniformity or dissolution.
2. A specific dry-granulation process that limits segregation.
3. A composition with defined ratios of MPA, binder, disintegrant, and lubricant.
4. A moisture-control system that improves stability.
5. A taste-masked MPA particle or multiparticulate system.
6. A rapid-disintegration dosage form with defined performance limits.
7. A combination package that improves adherence or reduces dosing errors.
8. A manufacturing process with validated content-uniformity advantages.

The patent must claim a technical result that is difficult to achieve by routine formulation work. Generic excipient substitution alone is vulnerable to obviousness challenges and may be difficult to defend commercially.

What is the Orange Book status of Provera and how does it affect development?

The commercial risk profile is primarily generic competition. FDA’s Orange Book records approved drug products, patent information submitted by NDA holders, and regulatory exclusivity data. A developer should distinguish the branded NDA, active generic listings, listed patents, and any discontinued presentations.[4]

For an old oral progestin tablet, the original composition and core therapeutic use are generally not expected to provide an active exclusivity barrier. The relevant regulatory questions are:

• Whether the reference listed drug remains eligible for ANDA comparison.
• Which strengths are currently approved and commercially available.
• Whether any listed patents remain unexpired.
• Whether the reference product has a current therapeutic-equivalence designation.
• Whether an applicant can file under Paragraph I, II, III, or IV certification.
• Whether formulation differences require a suitability petition or 505(b)(2) pathway.

How do Paragraph IV challenges affect generic entry?

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed product. For an old product with no meaningful unexpired patent barrier, the principal route may instead involve Paragraph I or II certifications, depending on the Orange Book record.

Generic entry timing can be affected by:

• FDA review and approval timing
• First-filer status
• Patent-listing disputes
• Reference-product availability
• Manufacturing readiness
• ANDA deficiencies
• Commercial launch decisions
• State substitution and payer contracting

A formulation patent filed for a differentiated MPA product could create a new Paragraph IV exposure. The patent owner would need to show that the listed claims cover the approved product or an approved method of use, not merely an internal development concept.

When does Provera lose exclusivity?

The original Provera product has long passed the period of ordinary small-molecule market exclusivity. The commercial market is therefore governed by generic competition rather than by a near-term patent cliff.

Exclusivity category	Provera oral tablet position
New chemical entity exclusivity	Expired or no longer commercially relevant
Original composition patent	Expected to be expired
Generic entry	Established
Formulation exclusivity	No broad, durable barrier apparent from the conventional tablet format
Current competitive risk	Price erosion, multi-source generic substitution, and supply competition
Lifecycle opportunity	New dosage form, patient-specific excipient profile, or differentiated packaging

A follow-on manufacturer should model pricing against a multi-source generic market, not against branded Provera pricing. Revenue depends more on volume, channel contracts, manufacturing cost, and shortage resilience than on premium brand positioning.

Which commercial segments are most attractive?

Retail generic tablets

Retail pharmacy is the largest immediate opportunity for a conventional generic. The product has familiar strengths and established prescribing patterns. Competition is likely to be price-driven, with limited ability to command a premium.

Institutional and public-sector procurement

Hospitals, public-health systems, correctional facilities, and government purchasers may value:

• Reliable supply
• Competitive unit cost
• Simple excipient labeling
• Multiple strengths
• Unit-dose packaging
• Serialization and traceability
• Low product discontinuation risk

A lactose-free product may have value in institutional settings where formulary standardization reduces medication-selection complexity.

Specialty and women’s health channels

A differentiated MPA product could be positioned through women’s health clinics, specialty pharmacies, and telehealth channels. The opportunity is stronger where the product offers a clear patient benefit, such as easier swallowing, lower excipient burden, or packaging that supports cyclic dosing.

Contract manufacturing and licensing

The most practical licensing opportunities are:

• Regional rights to an approved generic
• Technology transfer for a low-dose blending process
• Co-development of a lactose-free or rapid-disintegration tablet
• Supply agreements for a dual-source product
• Private-label distribution
• Portfolio bundling with estrogen products or other women’s health medicines

A licensing transaction is more likely to attract interest if it includes approved dossiers, validated commercial batches, regulatory rights in multiple jurisdictions, or an established manufacturing site.

How does Provera compare with other progestin products?

Product or ingredient	Main distinction from oral MPA tablets	Excipient and commercial implication
Medroxyprogesterone acetate tablets	Immediate-release oral progestin	Low-cost generic market; excipient differentiation must be clinically or operationally relevant
Micronized progesterone capsules	Different active ingredient and dosage form	Softgel excipients, gelatin, oils, and dissolution issues create a different development profile
Norethindrone tablets	Alternative oral progestin	Competes in selected gynecologic indications but is not an automatic therapeutic substitute
Megestrol acetate	Different progestin with different indications	More relevant to appetite and cachexia markets than routine gynecologic use
Depot medroxyprogesterone acetate injection	Long-acting injectable route	Sterility, suspension properties, device or vial requirements, and injection-site considerations dominate
Combined estrogen-progestin products	Combination therapy	Requires compatibility, dose-ratio control, and combination-product regulatory analysis

Provera’s advantage is formulation simplicity. Its weakness is limited differentiation in a mature generic category.

What manufacturing and intellectual-property barriers remain?

The principal technical barriers are not the identity of the excipients. They are process control and product performance.

Critical controls include:

• MPA assay and content uniformity
• Blend segregation
• Lubrication time
• Tablet hardness and friability
• Disintegration
• Dissolution across relevant pH conditions
• Impurity formation
• Moisture uptake
• Color and appearance consistency
• Packaging integrity
• Stability under accelerated and long-term conditions

FDA’s inactive ingredient database can support excipient selection by identifying prior use in approved drug products, but prior use does not eliminate the need for product-specific safety, quality, and regulatory assessment.[5] SUPAC-IR principles are relevant when post-approval changes affect composition, scale, manufacturing process, or site.[6]

Geographic protection is likely to be limited for the basic tablet. A stronger international strategy may come from:

• Country-specific registrations
• Local manufacturing
• Tender eligibility
• Regional supply agreements
• Trademark protection
• Packaging and serialization compliance
• Local excipient and API sourcing

What FDA regulatory pathway applies to a new Provera formulation?

Conventional generic tablet

An ANDA is the most efficient route for a formulation that is pharmaceutically equivalent to the reference product and satisfies FDA bioequivalence requirements. Excipients may differ, but the applicant must demonstrate that the differences do not compromise safety, performance, or therapeutic equivalence.[2]

505(b)(2) formulation

A 505(b)(2) application may be appropriate for:

• Orally disintegrating tablets
• Modified-release products
• New strengths or dosing regimens
• New routes of administration
• Products with a clinically meaningful formulation change
• Products relying partly on FDA findings for an approved MPA product

This route can support differentiation but may require additional clinical or pharmacokinetic evidence.

Combination product

A combined estrogen-MPA product could address adherence and regimen simplification. It would also create new development requirements for dose compatibility, stability, clinical labeling, and safety. The commercial opportunity is larger than a filler substitution but the regulatory and clinical burden is materially higher.

What is the revenue exposure and launch risk?

A conventional MPA generic has modest per-unit economics and high price sensitivity. Revenue depends on:

• Number of approved manufacturers
• Wholesale acquisition price
• Pharmacy benefit manager placement
• Medicaid and government contracts
• Generic substitution rates
• Back-order frequency
• Manufacturing cost per tablet
• Strength mix
• Packaging format
• Geographic scope

The 2.5 mg, 5 mg, and 10 mg strengths should be evaluated separately. Demand may not be evenly distributed across strengths, and maintaining all strengths can increase inventory and validation costs. A staged launch beginning with the highest-volume strength may reduce working-capital exposure, but a complete strength portfolio can improve contracting leverage.

The strongest launch scenario is a reliable, low-cost product with at least one defensible operational advantage: lactose-free composition, robust content uniformity, short lead times, or institutional packaging. The weakest scenario is an undifferentiated tablet entering a crowded market without a cost or supply advantage.

How strong is the patent estate for Provera?

The core patent estate is weak as a commercial barrier because the active ingredient, conventional oral tablet, and established indications have been in use for decades. The most realistic IP strategy is a narrow improvement patent tied to a measurable formulation or manufacturing advantage.

IP category	Commercial strength
Original MPA composition	Low; historical protection is expired
Conventional immediate-release tablet	Low
Standard excipient substitution	Low
Low-dose uniformity process	Moderate if technically specific and difficult to design around
Taste-masked or orally disintegrating product	Moderate, depending on claims and clinical differentiation
Packaging and adherence system	Low to moderate
New combination product	Moderate, with higher regulatory costs
Manufacturing know-how	Potentially high operational value, but not necessarily patent-protected

Trade secrets may be more useful than patents for blend order, granulation parameters, in-process controls, and scale-up methods. Trade-secret protection does not prevent independent development, but it can preserve manufacturing yield and product consistency.

Key Takeaways

• Provera is an oral medroxyprogesterone acetate tablet available in 2.5 mg, 5 mg, and 10 mg strengths.
• The conventional tablet market is mature and genericized, with limited opportunity for premium pricing.
• Reference-product excipients include lactose monohydrate, sucrose, corn starch, calcium stearate, and talc, with colorants varying by strength.
• The strongest formulation opportunity is a lactose-free, low-dose-content-uniformity tablet with robust supply economics.
• Orally disintegrating, mini-tablet, taste-masked, and adherence-oriented products could support a 505(b)(2) strategy.
• Standard excipient substitution is unlikely to create meaningful patent protection.
• Manufacturing know-how, supplier redundancy, and reliable supply may create more value than composition patents.
• A conventional generic should be evaluated against multi-source generic pricing, not branded Provera pricing.
• Generic entry risk is high because the product has long-established therapeutic use and no obvious durable barrier in the basic tablet format.
• Licensing opportunities are strongest for approved dossiers, regional commercialization rights, differentiated formulations, and contract manufacturing capacity.

FAQs

Is lactose-free medroxyprogesterone acetate commercially viable?

Yes. A lactose-free tablet can target patients with lactose sensitivity and institutional buyers seeking simplified excipient profiles. Its success depends on maintaining dissolution, content uniformity, stability, and tablet manufacturability.

Can a manufacturer patent a new Provera excipient combination?

Possibly, but the claims must cover a non-obvious composition or process with a technical benefit. Routine substitution of lactose with microcrystalline cellulose or mannitol is unlikely to provide strong protection.

Would an orally disintegrating medroxyprogesterone tablet receive generic approval?

Not necessarily. If the dosage form is materially different from the reference tablet, the product may require a 505(b)(2) application rather than a conventional ANDA.

Is Depo-Provera an excipient or formulation opportunity for Provera tablets?

No. Depo-Provera is an injectable medroxyprogesterone acetate suspension. It requires sterile manufacturing, suspension control, container-closure qualification, and injectable-product regulatory compliance.

What is the most defensible commercial advantage for a new Provera generic?

Reliable supply supported by strong low-dose content uniformity, qualified alternate excipient sources, competitive manufacturing cost, and a clear excipient profile is more defensible than an undifferentiated tablet composition.

References

1. Pfizer Laboratories. (2023). Provera (medroxyprogesterone acetate) tablets: Prescribing information. U.S. National Library of Medicine, DailyMed.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/types-applications/505b2-application

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

6. U.S. Food and Drug Administration. (1995). SUPAC-IR: Immediate-release solid oral dosage forms: Scale-up and post-approval changes. Center for Drug Evaluation and Research.